SCIENCE@home

Post-transplant lymphoproliferative disorder.

L. Kalinová,J. Indráková,P. Bachleda

Published 2009 in Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia

ABSTRACT

BACKGROUND Posttransplant lymphoproliferative disorder (PTLD) is increasingly recognized as a serious complication of solid organ transplantation in both children and adults. Factors associated with increased risk of PTLD include mismatch of recipient and donor EBV serologic status (seronegative recipient with seropositive donor), and intensive drug-induced immunosuppression. METHODS AND RESULTS We searched MEDLINE for articles published since 1970 to January 2009. Search terms included posttransplant lymphoproliferative disorder, immunosuppression, posttransplant malignancy, treatment, antiviral agents, rituximab, interferon alpha, chemotherapy, radiation, surgery. Studies in English of adult and pediatric populations after solid organ transplantation were selected and analyzed. CONCLUSION Screening of patients at risk and balancing the intensity of immunosuppression against the risk of allograft rejection could reduce the risk of developing PTLD. In patients who develop PTLD, the severity and extent of disease should be examined and an individualized treatment plan including immunosuppression reduction and other agents should accordingly be chosen.

PUBLICATION RECORD

  • Publication year

    2009

  • Venue

    Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia

  • Publication date

    2009-12-01

  • Fields of study

    Medicine

  • Identifiers
    DOI 10.5507/BP.2009.043PMID 20208963
  • External record

    Open on Semantic Scholar

  • Source metadata

    Semantic Scholar, PubMed

CITATION MAP

EXTRACTION MAP

CLAIMS

  • No claims are published for this paper.

CONCEPTS

  • No concepts are published for this paper.

REFERENCES

Showing 1-89 of 89 references · Page 1 of 1

CITED BY

Showing 1-78 of 78 citing papers · Page 1 of 1